$195 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 6 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARCELLX INC. | $141,605,084 | +13.5% | 3,946,630 | 0.0% | 72.57% | +34.9% | ||
| MINERALYS THERAPEUTICS | $17,066,646 | -44.2% | 1,794,600 | 0.0% | 8.75% | -33.7% | ||
| DSGN | DESIGN THERAPEUTICS INC | $15,402,483 | -62.5% | 6,526,476 | 0.0% | 7.89% | -55.5% | |
| SBTX | ARS PHARMACEUTICALS | $15,168,773 | -43.6% | 4,012,903 | 0.0% | 7.77% | -32.9% | |
| EFFECTOR THERAPEUTICS INC | $4,025,047 | -28.0% | 6,822,114 | 0.0% | 2.06% | -14.5% | ||
| NKTX | NKARTA INC. | $1,853,333 | -36.5% | 1,333,333 | 0.0% | 0.95% | -24.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
| EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
| ARCELLX INC. | 7 | Q3 2023 | 72.6% |
| NKARTA INC. | 6 | Q3 2023 | 8.0% |
| ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
| MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR/A | 2023-05-19 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-08 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.